Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What a great idea to have a Recovery Lifestyle network.....I’m going back in to buy, the price is right!
From VSUL 10Q:
"We believe that our cash on hand will be sufficient to fund our operations until August 31, 2017."
Good volume. $.68 is next then $.85....
I am starting to see the Cold Brew everywhere. It is the only Cold Brew I have tried that actually tastes good....really good.
Something tells me they are doing really well. My guess is that they are trying to walk the line between being responsible with what they are sharing, and keeping shareholders in a happy place. I would rather have them kick butt and tell us later than put out hopeful info that doesn't happen.
Time to pick up some more shares I think....long and strong on KRED!!
Looks like we finally have some volume.......
Great info, thank you
After doing some research, I can say you are 100% correct in your assessment.
This company seems to be in position to benefit from where this industry is going....why all the recent weakness? Seems like a buy to me.....
Not sure of any weakness on the horizon with the cold brew pushing up the numbers, but I guess you never know. I am actually kind of surprised that it hasn't jumped more recently with all the positive news.
I think that their cold brew is going to take them to the promised land.....
http://www.bevnet.com/news/2017/konared-corporation-announces-98-revenue-increase-2016?utm_source=BevNET.com%2C+Inc.+List&utm_campaign=7fb9a8e1ba-mailchimp&utm_medium=email&utm_term=0_f63e064108-7fb9a8e1ba-142259874
I agree. Close a deal already!
I agree, nothing new if you've been following it. The Biomedix (and by association Establishment Labs) info is good....but I would love to see more definitive about where things are going--hopefully they will make progress public soon. At least they are starting to communicate. Hopefully that trend will continue. This technology has so much potential.....they just need to finally capitalize on it.
What is going to give it a bounce?
Anything going on with this company? Looked at it a while back and it seemed like it had some promise....
Good stuff. You would think that the volume and price would've bumped up significantly with this info.
Any thoughts on why?
What is up with the low volume today?
I sure hope you are right......
Do you guys think Trump is going to be good or bad for Apple? Are we near the top or ready for an adjustment??
Thoughts......?
Visualant Announces Shareholder Update
SEATTLE--(BUSINESS WIRE)--Mar. 8, 2017-- Visualant, Inc. (OTCQB: VSUL) – a provider of chromatic-based identification, authentication and diagnostic solutions, with its ChromaID™ technology, released today a letter from its Founder and Chief Executive Officer providing an overview of the Company’s technology and an update on recent activities of the Company.
Dear Shareholders,
I am pleased to update you on Visualant and its recent activities. I am very excited about the prospects for our Company in 2017 and beyond. As many of you know, last year was a challenging year at Visualant. After much effort and hard work, we have moved the Company forward, although our stock price is not a reflection of the true value of the Company and its technology. Considering our advanced technology, our IP portfolio and ChromaID’s nearly unlimited opportunities as a platform technology applicable to so many industries, the value of our Company and its stock has not yet been recognized by the marketplace.
I would like to begin by reviewing the basics of Visualant’s award-winning technology and highlighting some of its compelling attributes and broad applications.
Almost everything in nature has a unique chromatic signature. Visualant’s award-winning technology, ChromaID, uses light to authenticate, identify and diagnose a wide variety of matter with accuracies at the wavelength of a photon. Traditional methods require the use of specialized and bulky equipment such as spectrophotometers and complex laboratory analysis which adds cost and time.
ChromaID is a platform technology that simplifies this process with its pioneering method of using structured light, a disruptive breakthrough in photonics, harnessing the power of the spectrophotometer into a handheld device at a competitive price.
Using a patented technology that includes a series of frequency-specific light-emitting diodes (LEDs), ChromaID creates a unique chromatic signature with thousands of data points providing a high degree of accuracy in a fraction of a second. This allows for instantaneous identification and analysis; saving time and increasing productivity.
ChromaID is available for licensing in collaboration with strategic partners for a variety of proprietary applications and commercial needs.
ChromaID is a sensor technology which has broad applications in the world of the Internet of Things (IoT).
ChromaID technology can potentially be integrated in to many Original Equipment Manufacturer (OEM) products, including mobile and tablet devices.
ChromaID devices are portable and field-deployable and enable real-time results.
ChromaID devices are low-cost, scalable systems that can be offered at lower prices than all known current competing technologies.
ChromaID Signature Reference Library™ databases are easy to build and can be stored locally or accessed via cloud-based applications. Over time, these Reference Library databases can become a significant asset of the Company.
Patents:
The Company currently has 10 issued patents and 20 patents pending on our current technology and its applications. As we have previously announced, we have patents pending relating to everything from food safety, to diamond grading, to ascertaining blood glucose levels. ChromaID technology can be used to authenticate anything from manufactured goods, driver’s licenses and access cards, pharmaceuticals and beyond. ChromaID can identify e-Coli on meat, explosive residue on a terrorist’s hand and counterfeit currency.
ChromaID, as mentioned above, is also a sensor technology which exists in the environment known as the Internet of Things or IoT. We envision a time when literally millions or billions of our sensors can be doing identification, authentication and diagnostics remotely connected to the Internet. Critical infrastructure and national security are two significant areas of potential application for the sensor IoT focus of ChromaID.
There are other potential developments underway which we will be able to announce over time as we seek development partners to expand the reach and markets for our ChromaID technology
The Future:
The Company’s commercialization plan includes three priorities for 2017: continue to mature the technology, expand our work in security applications and add commercialization partners. The Company plans to produce a next generation ChromaID system that will build on the success of the previous model while incorporating the feedback we have received from potential customers. Potential customers have asked for enhancements that will better demonstrate how the ChromaID will work in their applications. The Company believes it can incorporate these enhancements at a relatively low cost and that these enhancements will speed the path to commercialization.
Events impacting the growth of our business over the past year and beyond include our Joint Development Agreements with Intellicheck Mobilisa and BIOMEDX. Intellicheck, a leader in authentication is focused on utilizing ChromaID for the authentication of identification cards including driver’s licenses and access control cards. BIOMEDX is a software company on the forefront of deploying new holographic technology with a myriad of applications in health care specifically for plastic and reconstructive surgery. The BIOMEDX agreement proposes to utilize ChromaID technology to enhance the natural color, contour and elasticity of skin to closely match the patient’s and provide the patient an enhanced post-surgical preview of their appearance.
Intellicheck and BIOMEDX are two relationships providing opportunities for Visualant to access very large markets for its ChromaID technology. These are both multi-billion dollar global markets. Penetrating a small portion of these markets can provide Visualant significant initial revenue within the next twelve months and long term revenue streams from continuing deployment of our ChromaID technology in these and many other market sectors.
Management Growth:
Our team was also enhanced late this past year with the additions of Jeff Wilson and Randy Sprague:
Jeff Wilson joined us as our Chief Financial Officer and Secretary/Treasurer in September. Jeff has extensive background as a CFO of technology companies including six years as CFO of MicroVision, the developer of the virtual retinal display technology.
Randy Sprague is a new addition to our Scientific Advisory Board. Randy was formerly Chief Engineer at MicroVision and has deep experience bringing new technology to the market. We are thrilled to have both on the Visualant team.
We are appreciative of the support from those of you who are long term shareholders. We want you to know that we are committed to the long-term success of Visualant and focused on a positive outcome for all our shareholders.
Thank you for your support of the Company. Please do not hesitate to be in touch with me. I would love to hear from you.
Sincerely,
Ron Erickson
Founder and CEO
About Visualant, Inc.
Visualant™ is a public company whose shares trade under the stock symbol “VSUL.” The Visualant Spectral Pattern Matching™ (SPM) technology directs structured light onto a substance or material, through a liquid or gas, or off a surface, to capture a unique ChromaID™. A ChromaID can be used to identify, detect, or diagnosis markers invisible to the human eye. ChromaID scanner modules can be integrated into a variety of mobile or fixed-mount form factors. The patented, award-winning technology is disruptive, making it possible to effectively conduct analyses in the field that could only previously be performed by large and expensive lab-based tests. For more information on Visualant, visit the company’s website at www.visualant.net.
Safe Harbor Statement
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements (within the meaning of Section 27a of the Securities Act of 1933 and Section 21e of the Securities Exchange Act of 1934) regarding us and our business, financial condition, results of operations and prospects. Forward-looking statements in this press release reflect the good faith judgment of our management and are based on facts and factors currently known to us. Forward-looking statements are subject to risks and uncertainties, and actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements as a result of either the matters set forth or incorporated in this press release generally or certain economic and business factors, some of which may be unknown to and/or beyond the control of Visualant, Inc. Specifically, we are exposed to various risks related to our need for additional financing to support our technology development, the sale of a significant number of our shares of common stock could depress the price of our common stock, acquiring or investing in new businesses and ongoing operations, we may incur losses in the future and the market price of our common stock may be volatile,. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. We do not undertake, and we expressly disclaim, any obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of the press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170308005351/en/
Source: Visualant, Inc.
Visualant Contact:
Redwood Investment Group
Div of: Pillar Marketing Group, Inc
Tom Hemingway, 714-978-4425
Did a little more digging on Biomedx. Check out this guy Rudy Mazzocchi of Biomedx who is also exec chairman of Establishment Labs. This looks like the common denominator which may bring these 3 companies together in joint development deal.
https://www.linkedin.com/in/rudy-a-mazzocchi-15382139
Visualant has a development deal with Biomedx. The connection with Rudy, Visualant and
Establishment Labs is noteworthy. Establishment was financed last year for $28m. They are growing exponentially developing breast implant technologies and products
http://establishmentlabs.com/2016/07/establishment-labs-announces-completion-of-a-28-million-financing/
Anyone out there???
I’d take a close look at the Subsequent Events section on page F-26.
Looks to me like VSUL has really either cleaned or strengthened their balance sheet. $800k promissory notes extended, a big chunk converted?? TransTechs credit facility renewed.
Beyond that, a significant raise, in the aggregate of capital that took out the toxic instruments which was what forced the share price down so far.
What interests me most is this Pulse Bio deal, which I think is now called Biomedx. They are in a joint development and possible merger? The ceo of that company is also exec chairman of Establishment Labs. Do a little diligence on this company, it could get interesting.
I downloaded an ebook on the FAIMS technology and it looks to me like they may be complimentary--not a replacement to ChromaID. Plus VSUL seems to be a lot further down the track of commercialization.
http://www.owlstonenanotech.com/ultrafaims/imsms-news/ebook-next-5-years
Momentum as in they seem to have a little more trading volume lately, and have apparently raised some capital and made some interesting business development moves.
I think that you may be right....based on their high of over $9, that's a lot of write-off bang for the buck. Seems to have some momentum these days.
Trying to sort out the confusion from the recent jt development agreements with Pulse Biologics and Biomedx. It states Biomedx has a worldwide license from Pulse Evolution. What is Pulse Biologics, is there a connection somewhere?
VSUL seems to have more going for it now than in the past yet most shareholders sitting with big losses since the stock fell from $9 earlier this year. After tax loss selling ends, this could be an interesting play.
Visualant and BIOMEDX Sign Joint Development Agreement
December 07, 2016
Focus on ChromaID to Aid in Enhanced 3-D and Holographic Imaging for Certain Medical Procedures
SEATTLE--(BUSINESS WIRE)--Dec. 7, 2016-- Visualant, Inc. (OTCQB: VSUL) – a photonics technology development company providing chromatic-based identification, authentication and diagnostic solutions, with its ChromaID™ technology, announced today that it has entered into a Joint Development Agreement with BIOMEDX Group, Inc., to develop its ChromaID technology as an exclusive analytical photonic tool for Aesthetics, Dermatology and Plastic Surgery.
The BIOMEDX Group, Inc. is a technology company founded to develop and commercialize photo-realistic 3-D and holographic digital human modeling for the medical/healthcare industry. The Company is developing specialized, interactive applications for simulation programs to capture real-time, pre-procedural modeling of facial cosmetic and reconstructive surgical methods including computer generated human anatomy to display holographic physiologically accurate simulations of the human body, including the biometrics of actual tissue and organs. Visualant and BIOMEDX will be developing applications using Visualant’s photonic ChromaID technology to analyze and determine various characteristics of the skin and underlying subdermal tissue as it relates BIOMEDX enhanced 3-D and holographic imaging for dermatologic, plastic surgery and aesthetic applications, a multi-billion dollar global market.
BIOMEDX Group, Inc. is led by Rudy Mazzocchi, an internationally renowned biomedical and technology entrepreneur. Mazzocchi is also Executive Chairman of Establishment Labs, a global aesthetic company, and Executive Chairman of LAFORGE Optical, a heads-up display eyewear company. The medical/technology team at BIOMEDX includes Dr. Raghu Raghavan, former Professor of Computer Science & Radiology at Johns Hopkins University and an author of over 150 Research Publication and 37 Patents as its Chief Technical Officer; and Goal Chopra, MD, MBA, a Neurosurgeon, Ophthalmologist and entrepreneur, who holds a faculty position in Dept. of Human Anatomical Studies at Stanford University, and a former Investment Banker at Lazard and Business Development Director of Boston Scientific Corporation, as its Chief Medical Officer.
“We are very excited to work with Visualant to jointly develop and deploy their ChromaID technology into the medical/healthcare marketplace through our existing channel relationships,” stated Mazzocchi, BIOMEDX Chairman and Acting-CEO. “We believe this Joint Development undertaking will lead to advancing the ChromaID technology not only in these addressable markets but also other large global markets for the ChromaID technology.”
“Rudy Mazzocchi and his team have a deep and proven understanding of the biomedical marketplace and the opportunities it provides for our technology,” said Visualant CEO, President and Founder, Ron Erickson. “We are very excited to work with BIOMEDX through this Joint Development Agreement, as it expands the opportunities for us to not only develop our technology but also deploy our technology in the biomedical and med-tech global markets. We intend to become a leader in utilizing photonic technology in this and other important market segments.”
http://www.businesswire.com/news/home/20161207005372/en/Visualant-BIOMEDX-Sign-Joint-Development-Agreement